Irritable Bowel Syndrome and Control Volunteers: Diet Challenge
NCT ID: NCT06668922
Last Updated: 2025-12-09
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
NA
Total Enrollment
72 participants
Study Classification
INTERVENTIONAL
Study Start Date
2024-11-28
Study Completion Date
2030-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The study will investigate the relationship between fecal bile acids, short-chain fatty acids (SCFAs), and the gut microbiota in irritable bowel syndrome (IBS). The central hypothesis of this study is that specific shifts in the GI microbiome composition correlate with altered colonic SCFAs and BAs and contribute to IBS symptoms. Primary aims include: (a) identifying GI microbiome signatures in IBS subtypes (IBS-C and IBS-D) and matched controls, and test if microbiome signatures in these groups correlate with fecal SCFAs and bacterial fermentation of an indigestible carbohydrate (inulin) after a dietary challenge (fecal inulin), and (b) determining if GI microbiome signatures in IBS subtypes and controls correlate with fecal BAs or markers of SCFA production (fecal SCFAs or inulin) and test if BAs correlate with fecal SCFAs or inulin.
The target population is adults ages 18-65 years meeting Rome IV criteria for IBS (both diarrhea- and constipation-predominant, IBS-D and IBS-C) and asymptomatic controls. Primary outcomes will be fecal bile acid excretion and profile, short-chain fatty acid excretion and profile, colonic transit, and fecal microbiota. Secondary outcomes will be stool characteristics based on responses to validated bowel diaries. Stool samples will be collected from participants during the last 2 days of a 4-day 100 g fat diet and split into 3 samples for fecal microbiota, SCFA, and bile acid analysis.
The target population is adults ages 18-65 years meeting Rome IV criteria for IBS (both diarrhea- and constipation-predominant, IBS-D and IBS-C) and asymptomatic controls. Primary outcomes will be fecal bile acid excretion and profile, short-chain fatty acid excretion and profile, colonic transit, and fecal microbiota. Secondary outcomes will be stool characteristics based on responses to validated bowel diaries. Stool samples will be collected from participants during the last 2 days of a 4-day 100 g fat diet and split into 3 samples for fecal microbiota, SCFA, and bile acid analysis.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Irritable Bowel Syndrome and Control Volunteers: Diet Challenge
NCT03983434
IBS - Irritable Bowel Syndrome
TERMINATED
NA
Pathophysiological Effects of Persistently Colonized Microbiome on Irritable Bowel Syndrome
NCT06013410
Irritable Bowel Syndrome
RECRUITING
NA
The Effect of Inulin Supplementation in Individuals With IBS-C
NCT06945302
Inulin
IBS (Irritable Bowel Syndrome)
Nutritional Status
+1 more
COMPLETED
NA
The Role of Intestinal Inflammation in Irritable Bowel Syndrome (IBS)
NCT01072903
Inflammation
Colon, Irritable
Colonic Diseases, Functional
+1 more
COMPLETED
Fecal Metabolome and the Intestinal Microbiota in Irritable Bowel Syndrome
NCT02981888
IBS
COMPLETED
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
During the study:
Screening/Visit 1
* Participants will be asked to read and sign this informed consent after all questions about the study have been answered to satisfaction.
* This is a screening visit, and we may determine that a participant is ineligible to continue to participate in the study.
* The study team will collect medication and medical history.
* A physical exam will be performed by the physician. Vital signs and body measurements will be collected.
* Participants will be provided with a take-home lasagna meal (vegetarian and non-vegetarian option) and dessert.
* Participants will receive a stool collection kit and instructions for the collection, storage, and transportation of stool.
* Instructions will be provided for a low fiber, high fat diet for Days 2-4.
* Participants will be asked to complete diet recall using the ASA24 and a bowel pattern diary to record bowel symptoms over the course of the study.
* IBS participants will complete the irritable bowel syndrome severity scoring system questionnaires (IBS-SSS).
Day 2-4 (at home):
* Participants will record stool symptoms and patterns in a diary daily.
* Participants will be instructed to consume a low fiber diet (maximum one piece of fruit and 100 g of vegetables a day, and white flour instead of whole grain products), avoid alcohol, and start a 4-day 100 g fat diet.
* On the evening before Day 5, participants will be instructed to collect a stool sample at home and return during Visit 2.
Day 5 (Visit 2):
* Participants will return to the clinic on Day 5 after an overnight fast.
* Participants in the reproductive age range will be given a urine pregnancy test prior to inulin ingestion and the study team will confirm a negative test result.
* Participants will receive breakfast onsite. The non-vegetarian option will consist of pancakes, butter, syrup, hard-boiled eggs, and bacon. The vegetarian option will substitute the bacon with a cheese snack (approximately 790 to 840 kcal) along with 10 g inulin Orafti® powder) thoroughly mixed in 200 mL of water.
* Take-home meals will be provided for lunch and dinner and are to be consumed at 4 and 8 hours from breakfast.
* IBS participants will complete the irritable bowel syndrome severity scoring system (IBS-SSS) questionnaire.
* A stool sample will be collected on Day 5.
* Participants will continue to complete diet recall using the ASA24 and a bowel pattern diary to record bowel symptoms over the course of the study.
Day 6
* Participants will be instructed to collected a final stool sample (Day 6).
* Participants will continue to complete diet recall using the ASA24 and a bowel pattern diary to record bowel symptoms over the course of the study.
Day 7 (Visit 3)
• Participants will return to the clinic to return stool collections (Day 5 and Day 6), the daily diaries, and the IBS-SSS forms (if applicable).
Day 30-90 (Optional dietary follow-up): To further assess the utility of the 24 hour dietary recall, willing participants will be invited to participate in a an optional follow-up activity during which they will complete the Automated Self-Administered Dietary Assessment Tool with or without assistance of a trained interviewer. Interested volunteers will be contacted by phone and provided instructions on how to complete the tool online by the study team.
Screening/Visit 1
* Participants will be asked to read and sign this informed consent after all questions about the study have been answered to satisfaction.
* This is a screening visit, and we may determine that a participant is ineligible to continue to participate in the study.
* The study team will collect medication and medical history.
* A physical exam will be performed by the physician. Vital signs and body measurements will be collected.
* Participants will be provided with a take-home lasagna meal (vegetarian and non-vegetarian option) and dessert.
* Participants will receive a stool collection kit and instructions for the collection, storage, and transportation of stool.
* Instructions will be provided for a low fiber, high fat diet for Days 2-4.
* Participants will be asked to complete diet recall using the ASA24 and a bowel pattern diary to record bowel symptoms over the course of the study.
* IBS participants will complete the irritable bowel syndrome severity scoring system questionnaires (IBS-SSS).
Day 2-4 (at home):
* Participants will record stool symptoms and patterns in a diary daily.
* Participants will be instructed to consume a low fiber diet (maximum one piece of fruit and 100 g of vegetables a day, and white flour instead of whole grain products), avoid alcohol, and start a 4-day 100 g fat diet.
* On the evening before Day 5, participants will be instructed to collect a stool sample at home and return during Visit 2.
Day 5 (Visit 2):
* Participants will return to the clinic on Day 5 after an overnight fast.
* Participants in the reproductive age range will be given a urine pregnancy test prior to inulin ingestion and the study team will confirm a negative test result.
* Participants will receive breakfast onsite. The non-vegetarian option will consist of pancakes, butter, syrup, hard-boiled eggs, and bacon. The vegetarian option will substitute the bacon with a cheese snack (approximately 790 to 840 kcal) along with 10 g inulin Orafti® powder) thoroughly mixed in 200 mL of water.
* Take-home meals will be provided for lunch and dinner and are to be consumed at 4 and 8 hours from breakfast.
* IBS participants will complete the irritable bowel syndrome severity scoring system (IBS-SSS) questionnaire.
* A stool sample will be collected on Day 5.
* Participants will continue to complete diet recall using the ASA24 and a bowel pattern diary to record bowel symptoms over the course of the study.
Day 6
* Participants will be instructed to collected a final stool sample (Day 6).
* Participants will continue to complete diet recall using the ASA24 and a bowel pattern diary to record bowel symptoms over the course of the study.
Day 7 (Visit 3)
• Participants will return to the clinic to return stool collections (Day 5 and Day 6), the daily diaries, and the IBS-SSS forms (if applicable).
Day 30-90 (Optional dietary follow-up): To further assess the utility of the 24 hour dietary recall, willing participants will be invited to participate in a an optional follow-up activity during which they will complete the Automated Self-Administered Dietary Assessment Tool with or without assistance of a trained interviewer. Interested volunteers will be contacted by phone and provided instructions on how to complete the tool online by the study team.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Irritable Bowel Syndrome (IBS)
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NON_RANDOMIZED
Intervention Model
SINGLE_GROUP
Primary Study Purpose
DIAGNOSTIC
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Healthy volunteers
Adults ages 18-65 years with no prior history of gastrointestinal diseases or symptoms.
Group Type
EXPERIMENTAL
Inulin
Intervention Type
DIETARY_SUPPLEMENT
Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
Irritable Bowel Syndrome Patients with Diarrhea (IBS-D)
Patients with irritable bowel syndrome (IBS) with diarrhea, ages 18-65 years fulfilling Rome IV criteria for IBS.
Group Type
EXPERIMENTAL
Inulin
Intervention Type
DIETARY_SUPPLEMENT
Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
Irritable Bowel Syndrome Patients with Constipation (IBS-C)
Patients with irritable bowel syndrome (IBS) with constipation, ages 18-65 years fulfilling Rome IV criteria for IBS.
Group Type
EXPERIMENTAL
Inulin
Intervention Type
DIETARY_SUPPLEMENT
Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Inulin
Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
Intervention Type
DIETARY_SUPPLEMENT
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 18-75
* Individuals with irritable bowel syndrome (IBS)
* Healthy volunteers (healthy controls) with no prior history of gastrointestinal (GI) disease or symptoms
* No dietary restrictions other than vegetarian
* Individuals with irritable bowel syndrome (IBS)
* Healthy volunteers (healthy controls) with no prior history of gastrointestinal (GI) disease or symptoms
* No dietary restrictions other than vegetarian
Exclusion Criteria
* Inflammatory bowel disease, celiac disease, or certain types of abdominal cancer, as well as those with thyroid or liver issues
* Abdominal surgery or abdominal radiation within 6 months of study participation, with an exception for C-section or gallbladder removal
* Use of any prescription, over the counter, or herbal medications known to affect gastrointestinal function or study interpretation, such as opioids, inflammatory drugs or certain antidepressants, within 6 months prior to study participation for healthy volunteers, or within 2 days of study participation for participants with IBS.
* An exception will be permitted for limited use of stable low doses of antidepressants for individuals who have been taking them for a period greater than one month.
* Rescue medication such as Bisacodyl (dulcolax) to relieve severe constipation and allow for stool collection will be permitted when needed.
* Use of Ozempic and Ozempic-type medications
* Pregnant or breastfeeding women
* Antibiotic use within 3 months of study participation
* Use of prebiotics or probiotics within the 2 weeks before the study initiation
* Regular tobacco use within the past 6 months
* Abdominal surgery or abdominal radiation within 6 months of study participation, with an exception for C-section or gallbladder removal
* Use of any prescription, over the counter, or herbal medications known to affect gastrointestinal function or study interpretation, such as opioids, inflammatory drugs or certain antidepressants, within 6 months prior to study participation for healthy volunteers, or within 2 days of study participation for participants with IBS.
* An exception will be permitted for limited use of stable low doses of antidepressants for individuals who have been taking them for a period greater than one month.
* Rescue medication such as Bisacodyl (dulcolax) to relieve severe constipation and allow for stool collection will be permitted when needed.
* Use of Ozempic and Ozempic-type medications
* Pregnant or breastfeeding women
* Antibiotic use within 3 months of study participation
* Use of prebiotics or probiotics within the 2 weeks before the study initiation
* Regular tobacco use within the past 6 months
Minimum Eligible Age
17 Years
Maximum Eligible Age
65 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of California, Los Angeles
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Andrea S. Shin, MD
Associate Professor
Responsibility Role
PRINCIPAL_INVESTIGATOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of California, Los Angeles
Los Angeles, California, United States
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
United States
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Wong BS, Camilleri M, McKinzie S, Burton D, Graffner H, Zinsmeister AR. Effects of A3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in females with functional constipation. Am J Gastroenterol. 2011 Dec;106(12):2154-64. doi: 10.1038/ajg.2011.285. Epub 2011 Aug 30.
Reference Type
BACKGROUND
Chey WD, Camilleri M, Chang L, Rikner L, Graffner H. A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation. Am J Gastroenterol. 2011 Oct;106(10):1803-12. doi: 10.1038/ajg.2011.162. Epub 2011 May 24.
Reference Type
BACKGROUND
Walters JR, Johnston IM, Nolan JD, Vassie C, Pruzanski ME, Shapiro DA. The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid. Aliment Pharmacol Ther. 2015 Jan;41(1):54-64. doi: 10.1111/apt.12999. Epub 2014 Oct 20.
Reference Type
BACKGROUND
Musch MW, Bookstein C, Xie Y, Sellin JH, Chang EB. SCFA increase intestinal Na absorption by induction of NHE3 in rat colon and human intestinal C2/bbe cells. Am J Physiol Gastrointest Liver Physiol. 2001 Apr;280(4):G687-93. doi: 10.1152/ajpgi.2001.280.4.G687.
Reference Type
BACKGROUND
Murray RD, McClung HJ, Li BU, Ailabouni A. Stimulatory effects of short-chain fatty acids on colonic absorption in newborn piglets in vivo. J Pediatr Gastroenterol Nutr. 1989 Jan;8(1):95-101. doi: 10.1097/00005176-198901000-00018.
Reference Type
BACKGROUND
Fukumoto S, Tatewaki M, Yamada T, Fujimiya M, Mantyh C, Voss M, Eubanks S, Harris M, Pappas TN, Takahashi T. Short-chain fatty acids stimulate colonic transit via intraluminal 5-HT release in rats. Am J Physiol Regul Integr Comp Physiol. 2003 May;284(5):R1269-76. doi: 10.1152/ajpregu.00442.2002.
Reference Type
BACKGROUND
Mitsui R, Ono S, Karaki S, Kuwahara A. Neural and non-neural mediation of propionate-induced contractile responses in the rat distal colon. Neurogastroenterol Motil. 2005 Aug;17(4):585-94. doi: 10.1111/j.1365-2982.2005.00669.x.
Reference Type
BACKGROUND
Banasiewicz T, Krokowicz L, Stojcev Z, Kaczmarek BF, Kaczmarek E, Maik J, Marciniak R, Krokowicz P, Walkowiak J, Drews M. Microencapsulated sodium butyrate reduces the frequency of abdominal pain in patients with irritable bowel syndrome. Colorectal Dis. 2013 Feb;15(2):204-9. doi: 10.1111/j.1463-1318.2012.03152.x.
Reference Type
BACKGROUND
Mortensen PB, Andersen JR, Arffmann S, Krag E. Short-chain fatty acids and the irritable bowel syndrome: the effect of wheat bran. Scand J Gastroenterol. 1987 Mar;22(2):185-92. doi: 10.3109/00365528708991878.
Reference Type
BACKGROUND
Tana C, Umesaki Y, Imaoka A, Handa T, Kanazawa M, Fukudo S. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil. 2010 May;22(5):512-9, e114-5. doi: 10.1111/j.1365-2982.2009.01427.x. Epub 2009 Nov 10.
Reference Type
BACKGROUND
Treem WR, Ahsan N, Kastoff G, Hyams JS. Fecal short-chain fatty acids in patients with diarrhea-predominant irritable bowel syndrome: in vitro studies of carbohydrate fermentation. J Pediatr Gastroenterol Nutr. 1996 Oct;23(3):280-6. doi: 10.1097/00005176-199610000-00013.
Reference Type
BACKGROUND
Aguilera M, Cerda-Cuellar M, Martinez V. Antibiotic-induced dysbiosis alters host-bacterial interactions and leads to colonic sensory and motor changes in mice. Gut Microbes. 2015;6(1):10-23. doi: 10.4161/19490976.2014.990790. Epub 2015 Jan 20.
Reference Type
BACKGROUND
Jalanka-Tuovinen J, Salojarvi J, Salonen A, Immonen O, Garsed K, Kelly FM, Zaitoun A, Palva A, Spiller RC, de Vos WM. Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome. Gut. 2014 Nov;63(11):1737-45. doi: 10.1136/gutjnl-2013-305994. Epub 2013 Dec 5.
Reference Type
BACKGROUND
Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012 Jul;10(7):712-721.e4. doi: 10.1016/j.cgh.2012.02.029. Epub 2012 Mar 15.
Reference Type
BACKGROUND
Simren M, Brazier J, Coremans G, Dapoigny M, Muller-Lissner SA, Pace F, Smout AJ, Stockbrugger RW, Vatn MH, Whorwell PJ. Quality of life and illness costs in irritable bowel syndrome. Digestion. 2004;69(4):254-61. doi: 10.1159/000079846. Epub 2004 Jul 14.
Reference Type
BACKGROUND
Wedlake L, A'Hern R, Russell D, Thomas K, Walters JR, Andreyev HJ. Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2009 Oct;30(7):707-17. doi: 10.1111/j.1365-2036.2009.04081.x. Epub 2009 Jun 30.
Reference Type
BACKGROUND
Gracie DJ, Kane JS, Mumtaz S, Scarsbrook AF, Chowdhury FU, Ford AC. Prevalence of, and predictors of, bile acid malabsorption in outpatients with chronic diarrhea. Neurogastroenterol Motil. 2012 Nov;24(11):983-e538. doi: 10.1111/j.1365-2982.2012.01953.x. Epub 2012 Jul 5.
Reference Type
BACKGROUND
Winston J, Shenoy M, Medley D, Naniwadekar A, Pasricha PJ. The vanilloid receptor initiates and maintains colonic hypersensitivity induced by neonatal colon irritation in rats. Gastroenterology. 2007 Feb;132(2):615-27. doi: 10.1053/j.gastro.2006.11.014. Epub 2006 Nov 10.
Reference Type
BACKGROUND
Shin A, Camilleri M, Vijayvargiya P, Busciglio I, Burton D, Ryks M, Rhoten D, Lueke A, Saenger A, Girtman A, Zinsmeister AR. Bowel functions, fecal unconjugated primary and secondary bile acids, and colonic transit in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2013 Oct;11(10):1270-1275.e1. doi: 10.1016/j.cgh.2013.04.020. Epub 2013 Apr 30.
Reference Type
BACKGROUND
Alemi F, Poole DP, Chiu J, Schoonjans K, Cattaruzza F, Grider JR, Bunnett NW, Corvera CU. The receptor TGR5 mediates the prokinetic actions of intestinal bile acids and is required for normal defecation in mice. Gastroenterology. 2013 Jan;144(1):145-54. doi: 10.1053/j.gastro.2012.09.055. Epub 2012 Oct 3.
Reference Type
BACKGROUND
Mroz MS, Keating N, Ward JB, Sarker R, Amu S, Aviello G, Donowitz M, Fallon PG, Keely SJ. Farnesoid X receptor agonists attenuate colonic epithelial secretory function and prevent experimental diarrhoea in vivo. Gut. 2014 May;63(5):808-17. doi: 10.1136/gutjnl-2013-305088. Epub 2013 Aug 5.
Reference Type
BACKGROUND
Marshall JK, Thabane M, Garg AX, Clark WF, Salvadori M, Collins SM; Walkerton Health Study Investigators. Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery. Gastroenterology. 2006 Aug;131(2):445-50; quiz 660. doi: 10.1053/j.gastro.2006.05.053.
Reference Type
BACKGROUND
Neal KR, Hebden J, Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. BMJ. 1997 Mar 15;314(7083):779-82. doi: 10.1136/bmj.314.7083.779.
Reference Type
BACKGROUND
Taverniti V, Guglielmetti S. Methodological issues in the study of intestinal microbiota in irritable bowel syndrome. World J Gastroenterol. 2014 Jul 21;20(27):8821-36. doi: 10.3748/wjg.v20.i27.8821.
Reference Type
BACKGROUND
Simren M, Barbara G, Flint HJ, Spiegel BM, Spiller RC, Vanner S, Verdu EF, Whorwell PJ, Zoetendal EG; Rome Foundation Committee. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut. 2013 Jan;62(1):159-76. doi: 10.1136/gutjnl-2012-302167. Epub 2012 Jun 22.
Reference Type
BACKGROUND
Shukla R, Ghoshal U, Dhole TN, Ghoshal UC. Fecal Microbiota in Patients with Irritable Bowel Syndrome Compared with Healthy Controls Using Real-Time Polymerase Chain Reaction: An Evidence of Dysbiosis. Dig Dis Sci. 2015 Oct;60(10):2953-62. doi: 10.1007/s10620-015-3607-y. Epub 2015 Mar 18.
Reference Type
BACKGROUND
Lyra A, Rinttila T, Nikkila J, Krogius-Kurikka L, Kajander K, Malinen E, Matto J, Makela L, Palva A. Diarrhoea-predominant irritable bowel syndrome distinguishable by 16S rRNA gene phylotype quantification. World J Gastroenterol. 2009 Dec 21;15(47):5936-45. doi: 10.3748/wjg.15.5936.
Reference Type
BACKGROUND
Sundin J, Rangel I, Fuentes S, Heikamp-de Jong I, Hultgren-Hornquist E, de Vos WM, Brummer RJ. Altered faecal and mucosal microbial composition in post-infectious irritable bowel syndrome patients correlates with mucosal lymphocyte phenotypes and psychological distress. Aliment Pharmacol Ther. 2015 Feb;41(4):342-51. doi: 10.1111/apt.13055. Epub 2014 Dec 18.
Reference Type
BACKGROUND
Carroll IM, Ringel-Kulka T, Keku TO, Chang YH, Packey CD, Sartor RB, Ringel Y. Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2011 Nov;301(5):G799-807. doi: 10.1152/ajpgi.00154.2011. Epub 2011 Jul 7.
Reference Type
BACKGROUND
Pozuelo M, Panda S, Santiago A, Mendez S, Accarino A, Santos J, Guarner F, Azpiroz F, Manichanh C. Reduction of butyrate- and methane-producing microorganisms in patients with Irritable Bowel Syndrome. Sci Rep. 2015 Aug 4;5:12693. doi: 10.1038/srep12693.
Reference Type
BACKGROUND
Rajilic-Stojanovic M, Biagi E, Heilig HG, Kajander K, Kekkonen RA, Tims S, de Vos WM. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology. 2011 Nov;141(5):1792-801. doi: 10.1053/j.gastro.2011.07.043. Epub 2011 Aug 5.
Reference Type
BACKGROUND
Rigsbee L, Agans R, Shankar V, Kenche H, Khamis HJ, Michail S, Paliy O. Quantitative profiling of gut microbiota of children with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol. 2012 Nov;107(11):1740-51. doi: 10.1038/ajg.2012.287.
Reference Type
BACKGROUND
Carroll IM, Ringel-Kulka T, Siddle JP, Klaenhammer TR, Ringel Y. Characterization of the fecal microbiota using high-throughput sequencing reveals a stable microbial community during storage. PLoS One. 2012;7(10):e46953. doi: 10.1371/journal.pone.0046953. Epub 2012 Oct 5.
Reference Type
BACKGROUND
Durban A, Abellan JJ, Jimenez-Hernandez N, Artacho A, Garrigues V, Ortiz V, Ponce J, Latorre A, Moya A. Instability of the faecal microbiota in diarrhoea-predominant irritable bowel syndrome. FEMS Microbiol Ecol. 2013 Dec;86(3):581-9. doi: 10.1111/1574-6941.12184. Epub 2013 Aug 23.
Reference Type
BACKGROUND
Carroll IM, Ringel-Kulka T, Siddle JP, Ringel Y. Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil. 2012 Jun;24(6):521-30, e248. doi: 10.1111/j.1365-2982.2012.01891.x. Epub 2012 Feb 20.
Reference Type
BACKGROUND
Malinen E, Krogius-Kurikka L, Lyra A, Nikkila J, Jaaskelainen A, Rinttila T, Vilpponen-Salmela T, von Wright AJ, Palva A. Association of symptoms with gastrointestinal microbiota in irritable bowel syndrome. World J Gastroenterol. 2010 Sep 28;16(36):4532-40. doi: 10.3748/wjg.v16.i36.4532.
Reference Type
BACKGROUND
Jeffery IB, O'Toole PW, Ohman L, Claesson MJ, Deane J, Quigley EM, Simren M. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut. 2012 Jul;61(7):997-1006. doi: 10.1136/gutjnl-2011-301501. Epub 2011 Dec 16.
Reference Type
BACKGROUND
Chassard C, Dapoigny M, Scott KP, Crouzet L, Del'homme C, Marquet P, Martin JC, Pickering G, Ardid D, Eschalier A, Dubray C, Flint HJ, Bernalier-Donadille A. Functional dysbiosis within the gut microbiota of patients with constipated-irritable bowel syndrome. Aliment Pharmacol Ther. 2012 Apr;35(7):828-38. doi: 10.1111/j.1365-2036.2012.05007.x. Epub 2012 Feb 8.
Reference Type
BACKGROUND
Duboc H, Rainteau D, Rajca S, Humbert L, Farabos D, Maubert M, Grondin V, Jouet P, Bouhassira D, Seksik P, Sokol H, Coffin B, Sabate JM. Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil. 2012 Jun;24(6):513-20, e246-7. doi: 10.1111/j.1365-2982.2012.01893.x. Epub 2012 Feb 22.
Reference Type
BACKGROUND
Stephen AM, Haddad AC, Phillips SF. Passage of carbohydrate into the colon. Direct measurements in humans. Gastroenterology. 1983 Sep;85(3):589-95.
Reference Type
BACKGROUND
Le Gall G, Noor SO, Ridgway K, Scovell L, Jamieson C, Johnson IT, Colquhoun IJ, Kemsley EK, Narbad A. Metabolomics of fecal extracts detects altered metabolic activity of gut microbiota in ulcerative colitis and irritable bowel syndrome. J Proteome Res. 2011 Sep 2;10(9):4208-18. doi: 10.1021/pr2003598. Epub 2011 Aug 8.
Reference Type
BACKGROUND
Ridlon JM, Kang DJ, Hylemon PB. Bile salt biotransformations by human intestinal bacteria. J Lipid Res. 2006 Feb;47(2):241-59. doi: 10.1194/jlr.R500013-JLR200. Epub 2005 Nov 18.
Reference Type
BACKGROUND
Wingate DL, Phillips SF, Hofmann AF. Effect of glycine-conjugated bile acids with and without lecithin on water and glucose absorption in perfused human jejunum. J Clin Invest. 1973 May;52(5):1230-6. doi: 10.1172/JCI107290.
Reference Type
BACKGROUND
De Smet I, Van Hoorde L, Vande Woestyne M, Christiaens H, Verstraete W. Significance of bile salt hydrolytic activities of lactobacilli. J Appl Bacteriol. 1995 Sep;79(3):292-301. doi: 10.1111/j.1365-2672.1995.tb03140.x.
Reference Type
BACKGROUND
Dussurget O, Cabanes D, Dehoux P, Lecuit M, Buchrieser C, Glaser P, Cossart P; European Listeria Genome Consortium. Listeria monocytogenes bile salt hydrolase is a PrfA-regulated virulence factor involved in the intestinal and hepatic phases of listeriosis. Mol Microbiol. 2002 Aug;45(4):1095-106. doi: 10.1046/j.1365-2958.2002.03080.x.
Reference Type
BACKGROUND
Stellwag EJ, Hylemon PB. Characterization of 7-alpha-dehydroxylase in Clostridium leptum. Am J Clin Nutr. 1978 Oct;31(10 Suppl):S243-S247. doi: 10.1093/ajcn/31.10.S243.
Reference Type
BACKGROUND
Wells JE, Berr F, Thomas LA, Dowling RH, Hylemon PB. Isolation and characterization of cholic acid 7alpha-dehydroxylating fecal bacteria from cholesterol gallstone patients. J Hepatol. 2000 Jan;32(1):4-10. doi: 10.1016/s0168-8278(00)80183-x.
Reference Type
BACKGROUND
Wells JE, Williams KB, Whitehead TR, Heuman DM, Hylemon PB. Development and application of a polymerase chain reaction assay for the detection and enumeration of bile acid 7alpha-dehydroxylating bacteria in human feces. Clin Chim Acta. 2003 May;331(1-2):127-34. doi: 10.1016/s0009-8981(03)00115-3.
Reference Type
BACKGROUND
Kitahara M, Takamine F, Imamura T, Benno Y. Clostridium hiranonis sp. nov., a human intestinal bacterium with bile acid 7alpha-dehydroxylating activity. Int J Syst Evol Microbiol. 2001 Jan;51(Pt 1):39-44. doi: 10.1099/00207713-51-1-39.
Reference Type
BACKGROUND
Fujita K, Kaku M, Yanagase Y, Ezaki T, Furuse K, Ozawa A, Saidi SM, Sang WK, Waiyaki PG. Physicochemical characteristics and flora of diarrhoeal and recovery faeces in children with acute gastro-enteritis in Kenya. Ann Trop Paediatr. 1990;10(4):339-45. doi: 10.1080/02724936.1990.11747455.
Reference Type
BACKGROUND
Balamurugan R, Janardhan HP, George S, Raghava MV, Muliyil J, Ramakrishna BS. Molecular studies of fecal anaerobic commensal bacteria in acute diarrhea in children. J Pediatr Gastroenterol Nutr. 2008 May;46(5):514-9. doi: 10.1097/MPG.0b013e31815ce599.
Reference Type
BACKGROUND
Albert MJ, Bhat P, Rajan D, Maiya PP, Pereira SM, Baker SJ. Faecal flora of South Indian infants and young children in health and with acute gastroenteritis. J Med Microbiol. 1978 May;11(2):137-43. doi: 10.1099/00222615-11-2-137.
Reference Type
BACKGROUND
Boets E, Deroover L, Houben E, Vermeulen K, Gomand SV, Delcour JA, Verbeke K. Quantification of in Vivo Colonic Short Chain Fatty Acid Production from Inulin. Nutrients. 2015 Oct 28;7(11):8916-29. doi: 10.3390/nu7115440.
Reference Type
BACKGROUND
Camilleri M, Shin A, Busciglio I, Carlson P, Acosta A, Bharucha AE, Burton D, Lamsam J, Lueke A, Donato LJ, Zinsmeister AR. Validating biomarkers of treatable mechanisms in irritable bowel syndrome. Neurogastroenterol Motil. 2014 Dec;26(12):1677-85. doi: 10.1111/nmo.12421. Epub 2014 Sep 22.
Reference Type
BACKGROUND
Palsson OS, Whitehead WE, van Tilburg MA, Chang L, Chey W, Crowell MD, Keefer L, Lembo AJ, Parkman HP, Rao SS, Sperber A, Spiegel B, Tack J, Vanner S, Walker LS, Whorwell P, Yang Y. Rome IV Diagnostic Questionnaires and Tables for Investigators and Clinicians. Gastroenterology. 2016 Feb 13:S0016-5085(16)00180-3. doi: 10.1053/j.gastro.2016.02.014. Online ahead of print.
Reference Type
BACKGROUND
Lane DJ, Pace B, Olsen GJ, Stahl DA, Sogin ML, Pace NR. Rapid determination of 16S ribosomal RNA sequences for phylogenetic analyses. Proc Natl Acad Sci U S A. 1985 Oct;82(20):6955-9. doi: 10.1073/pnas.82.20.6955.
Reference Type
BACKGROUND
Satinsky BM, Gifford SM, Crump BC, Moran MA. Use of internal standards for quantitative metatranscriptome and metagenome analysis. Methods Enzymol. 2013;531:237-50. doi: 10.1016/B978-0-12-407863-5.00012-5.
Reference Type
BACKGROUND
Caporaso JG, Lauber CL, Walters WA, Berg-Lyons D, Huntley J, Fierer N, Owens SM, Betley J, Fraser L, Bauer M, Gormley N, Gilbert JA, Smith G, Knight R. Ultra-high-throughput microbial community analysis on the Illumina HiSeq and MiSeq platforms. ISME J. 2012 Aug;6(8):1621-4. doi: 10.1038/ismej.2012.8. Epub 2012 Mar 8.
Reference Type
BACKGROUND
Kozich JJ, Westcott SL, Baxter NT, Highlander SK, Schloss PD. Development of a dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence data on the MiSeq Illumina sequencing platform. Appl Environ Microbiol. 2013 Sep;79(17):5112-20. doi: 10.1128/AEM.01043-13. Epub 2013 Jun 21.
Reference Type
BACKGROUND
Thomas MC, Thomas DK, Selinger LB, Inglis GD. spyder, a new method for in silico design and assessment of 16S rRNA gene primers for molecular microbial ecology. FEMS Microbiol Lett. 2011 Jul;320(2):152-9. doi: 10.1111/j.1574-6968.2011.02302.x. Epub 2011 May 25.
Reference Type
BACKGROUND
Schloss PD, Westcott SL, Ryabin T, Hall JR, Hartmann M, Hollister EB, Lesniewski RA, Oakley BB, Parks DH, Robinson CJ, Sahl JW, Stres B, Thallinger GG, Van Horn DJ, Weber CF. Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities. Appl Environ Microbiol. 2009 Dec;75(23):7537-41. doi: 10.1128/AEM.01541-09. Epub 2009 Oct 2.
Reference Type
BACKGROUND
Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJ, Holmes SP. DADA2: High-resolution sample inference from Illumina amplicon data. Nat Methods. 2016 Jul;13(7):581-3. doi: 10.1038/nmeth.3869. Epub 2016 May 23.
Reference Type
BACKGROUND
Gao X, Lin H, Revanna K, Dong Q. A Bayesian taxonomic classification method for 16S rRNA gene sequences with improved species-level accuracy. BMC Bioinformatics. 2017 May 10;18(1):247. doi: 10.1186/s12859-017-1670-4.
Reference Type
BACKGROUND
McMurdie PJ, Holmes S. Phyloseq: a bioconductor package for handling and analysis of high-throughput phylogenetic sequence data. Pac Symp Biocomput. 2012:235-46.
Reference Type
BACKGROUND
Tagliacozzi D, Mozzi AF, Casetta B, Bertucci P, Bernardini S, Di Ilio C, Urbani A, Federici G. Quantitative analysis of bile acids in human plasma by liquid chromatography-electrospray tandem mass spectrometry: a simple and rapid one-step method. Clin Chem Lab Med. 2003 Dec;41(12):1633-41. doi: 10.1515/CCLM.2003.247.
Reference Type
BACKGROUND
Vijayvargiya P, Camilleri M, Shin A, Saenger A. Methods for diagnosis of bile acid malabsorption in clinical practice. Clin Gastroenterol Hepatol. 2013 Oct;11(10):1232-9. doi: 10.1016/j.cgh.2013.04.029. Epub 2013 May 2.
Reference Type
BACKGROUND
Park J, Kim M, Kang SG, Jannasch AH, Cooper B, Patterson J, Kim CH. Short-chain fatty acids induce both effector and regulatory T cells by suppression of histone deacetylases and regulation of the mTOR-S6K pathway. Mucosal Immunol. 2015 Jan;8(1):80-93. doi: 10.1038/mi.2014.44. Epub 2014 Jun 11.
Reference Type
BACKGROUND
Dall'Amico R, Montini G, Pisanello L, Piovesan G, Bottaro S, Cracco AT, Zacchello G, Zacchello F. Determination of inulin in plasma and urine by reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Appl. 1995 Oct 6;672(1):155-9. doi: 10.1016/0378-4347(95)00209-2.
Reference Type
BACKGROUND
Heaton KW, Radvan J, Cripps H, Mountford RA, Braddon FE, Hughes AO. Defecation frequency and timing, and stool form in the general population: a prospective study. Gut. 1992 Jun;33(6):818-24. doi: 10.1136/gut.33.6.818.
Reference Type
BACKGROUND
Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. 1997 Apr;11(2):395-402. doi: 10.1046/j.1365-2036.1997.142318000.x.
Reference Type
BACKGROUND
Benjamini Y and Y. Hochberg. Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society 1995. Series B 57:289-300
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
24-0442
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
The Effect of Prebiotics on the Microbiome in Irritable Bowel Syndrome Patients: The Diet and Microbiome Study
NCT01829932
COMPLETED
NA
Effect of Chronic Feeding of Inulin And Methylcellulose on Colonic Fermentation
NCT06551961
RECRUITING
NA
Caecal pH as a Biomarker for Irritable Bowel Syndrome
NCT02360384
UNKNOWN
NA
Effects of Dietary Fibre in Irritable Bowel Syndrome (IBS)
NCT03803319
COMPLETED
NA
Fibre and Gas in Irritable Bowel Syndrome
NCT03265002
COMPLETED
NA
Diet Reintroduction Study in Irritable Bowel Syndrome
NCT03052439
COMPLETED
NA
Comparing the Effectiveness of 2 Diets for Patients With Irritable Bowel Syndrome
NCT01624610
COMPLETED
NA
Effects of Faecal Microbiota Transplantation in Patients With IBS
NCT03822299
COMPLETED
NA
Changes in Microbiota and Quality of Life in IBS
NCT05266287
UNKNOWN
NA
Multi Strain Probiotic Preparation in Patients With Irritable Bowel Syndrome
NCT04662957
COMPLETED
NA
Capsule Microbiota Sampling in IBS/Functional Gastrointestinal Disease
NCT06215222
RECRUITING
The Effect of Inulin in Irritable Bowel Syndrome
NCT06610188
COMPLETED
NA
Irritable Bowel Syndrome and Food Sensitivity
NCT02186743
COMPLETED
NA
Manipulation of Visceral Sensitivity and Immune System in IBS
NCT00418340
UNKNOWN
PHASE4
Use of A Complex Gut Bacterial Consortium (MITI 001) for the Treatment of Irritable Bowel Syndrome With Diarrhea
NCT07238790
NOT_YET_RECRUITING
EARLY_PHASE1
Efficacy of Probiotic Bacteria in Subjects With IBS or Functional Diarrhea/ Bloating
NCT00618904
COMPLETED
NA
A Clinical Trial Evaluating Diets for IBS
NCT05831306
UNKNOWN
NA
The Efficacy of Single-strain Probiotics in Patients With Irritable Bowel Syndrome
NCT05064930
COMPLETED
NA
The Effect of Dietary Intervention on Symptoms, Epigenetics, and Gut Microbiota in IBS
NCT03306381
COMPLETED
NA
Study to Determine the Effectiveness of the Probiotic E. Coli Strain M17 in Treating Irritable Bowel Syndrome (IBS)
NCT00194922
COMPLETED
PHASE2
Faecal Microbiota Transplantation in Irritable Bowel Syndrome
NCT02423421
UNKNOWN
PHASE2
Probiotics in Intestinal Bacterial Overgrowth
NCT02204891
COMPLETED
NA
The Stool Microbiome of Treated and Untreated IBS (Irritable Bowel Syndrome) Patients
NCT05972317
RECRUITING
NA
Mediterranean Diet and the Gut Microbiome
NCT03269032
COMPLETED
NA
Fecal Microbial Transplantation in Treatment of Irritable Bowel Syndrome; a Double Blinded Placebo Controlled Trial.
NCT02154867
COMPLETED
PHASE2